ACET Adicet Bio, Inc.

NEUTRAL Impact: 3/10 144
Horizon days Filed Apr 9, 2026 Processed 2mo ago SEC 0000947871-26-000417
Form 144 — notice of proposed sale of securities
Latest settled — T+20d ⚠ clustered
ACET ▲ +24.64% at T+20d
NEUTRAL call ✓ call won +24.64% · α vs SPY +17.07% · entry $6.86 → $8.55
Next anchor: T+60d in 20d
Currently $8.05 · +17.35% from $6.86 entry
Entry anchored
Apr 8, 03:59 PM ET
via Databento tick
T+1d
-1.46%
call -1.46% · α -1.40%
$6.76
settled 2mo ago
T+5d
+17.35%
call +17.35% · α +14.16%
$8.05
settled 8w ago
T+20d
+24.64%
call +24.64% · α +17.07%
$8.55
settled 5w ago
T+60d
call — · α —
in 20d

Price Chart

Loading chart...

Executive Summary

OrbiMed Advisors Israel II Ltd, acting on behalf of fund OrbiMed Israel Partners II, L.P., filed a Form 144 to notify intent to sell up to 40,416 shares of Adicet Bio common stock. The sale would occur on or after the filing date of April 8, 2026, through the Nasdaq Stock Market.

Actionable Insight

Monitor for actual sale execution in upcoming days; while the dollar amount is relatively small compared to ACET's $62M market cap, any insider-initiated selling in a microcap biotech could signal reduced conviction ahead of a catalyst or dilutive offering.

Key Facts

  • Reporting entity: OrbiMed Advisors Israel II Ltd (acting for OrbiMed Israel Partners II, L.P.)
  • Subject company: Adicet Bio, Inc. (ACET)
  • Number of shares proposed for sale: 40,416
  • Share type: Common Stock
  • Acquisition date: September 15, 2020, via merger
  • Planned sale method: Open market or privately negotiated transaction via Themis Trading LLC
  • Filing date: April 8, 2026

Financial Impact

Approximately $2.65 million based on current market price of $65.57 per share (40,416 shares × $65.57)

insider ownershippotential near-term supply

Risk Factors

  • Potential downward pressure on stock price if sale is executed in a short timeframe
  • Perception of negative sentiment from a long-standing institutional holder exiting part of its position

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0000947871-26-000417
Document: 0000947871-26-000417-index.html0000947871-26-000417
Document: 0000947871-26-000417.txt0000947871-26-000417
5 reports for ACET
Performance horizon
Filters
Rows
Reports for ACET — sortable, filterable
Type Now
May 20, 2026
23d ago
10-K/A
NEUTRAL ★ 2/10
$7.89 $9.31▲ +18.00%▲ +16.15%$8.05 (+2.03%)
May 13, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$8.41 $7.89▼ −6.18%▼ −5.47%$8.05 (−4.28%)
Apr 9, 2026
9w ago
144
NEUTRAL ★ 3/10
$6.86 $8.05▲ +17.35%▲ +14.16%$8.05 (+17.35%)
Apr 8, 2026
9w ago
144
NEUTRAL ★ 3/10
$6.55 $7.92▲ +20.92%▲ +17.40%$8.05 (+22.90%)
Mar 24, 2026
11w ago
EFFECT
NEUTRAL ★ 4/10
$6.69 $6.81▲ +1.79%▲ +2.22%$8.05 (+20.33%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (48h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access